Did QIAGEN beat earnings in Q4 2025?

Yes, QIAGEN beat its Q4 2025 outlook with adjusted diluted EPS of $0.62 CER versus guidance of ~$0.60 CER (+3.3%). Revenue grew +1% CER, ahead of the ~0% CER outlook.

What is QIAGEN's 2026 guidance?

QIAGEN guided FY 2026 net sales growth of ≥+5% CER and adjusted diluted EPS of ≥$2.50 CER, representing ≥5% EPS growth versus 2025's $2.40 CER.

Why did QIAGEN stock drop after earnings?

Despite beating Q4 outlook, QGEN shares fell 2.3% in aftermarket trading. The decline may reflect concerns about slower H1 2026 growth (~2-3% CER) before accelerating to 7-8% CER in H2, and currency headwinds impacting margins.

QIAGEN (QGEN)·Q4 2025 Earnings Summary

QIAGEN Q4 2025: EPS Beats Outlook, But Stock Slides 2% After Hours

February 4, 2026 · by Fintool AI Agent

Banner

QIAGEN (NYSE: QGEN) delivered solid Q4 2025 results that exceeded company guidance, with adjusted EPS of $0.62 beating the ~$0.60 outlook by 3.3% and revenue growth of +1% CER surpassing the flat outlook. Full-year 2025 adjusted operating margin expanded 80 basis points to 29.5% despite 80 bps of tariff headwinds. However, shares fell 2.3% in aftermarket trading to $50.51, potentially reflecting investor concerns about a slower first half in 2026 before growth accelerates.

Did QIAGEN Beat Earnings?

Yes — QIAGEN beat on both EPS and revenue growth versus its outlook.

Metric	Q4 2025 Actual	Company Outlook	Beat/Miss
Adj. Diluted EPS (CER)	$0.62	~$0.60	+3.3% Beat
Net Sales Growth (CER)	+1%	~0%	+1 ppt Beat
Net Sales (Actual Rates)	$540.4M	—	+3.7% YoY

For full-year 2025, QIAGEN also exceeded expectations:

Metric	FY 2025	FY 2024	YoY Change
Net Sales	$2.09B	$1.98B	+6%
Adj. Diluted EPS	$2.38	$2.18	+9.2%
Adj. Operating Margin	29.5%	28.7%	+80 bps
Operating Cash Flow	$654M	$674M	-3%

Ask Fintool AI Agent

What Drove Q4 Performance?

Growth pillar performance was mixed in Q4:

Product/Segment	Q4 2025 CER Growth	Key Driver
Sample Technologies	+5%	Automated consumables; Parse acquisition
QuantiFERON	+5%	Gains in U.S. and Europe
QIAstat-Dx	+15%	Double-digit panel demand; 150+ placements
QIAcuity	Double-digit consumables	Capital spending challenges on instruments
QDI	Double-digit	Genoox integration; >150K users globally

The quarter was marked by two key acquisitions:

Parse Biosciences (Dec 2025): Adds single-cell preparation and analysis via Evercode™ kits
Blood Culture ID Panels: Submitted for U.S. clearance and CE-IVDR registration, expanding syndromic testing

How Did the Stock React?

Timeframe	QGEN Price	Change
Close (Feb 4)	$51.71	-0.9%
Aftermarket	$50.51	-2.3%
Week Ago	$53.99	-4.2% from week ago
52-Week High	$57.82	-12.6% from high
52-Week Low	$37.63	+34.2% from low

Despite beating guidance, the stock declined. This may reflect:

Slower H1 2026 growth: Company guided ~2-3% CER in H1 before accelerating to 7-8% in H2
Currency & Tariff headwinds: ~1.5 ppt of margin headwind expected in 2026
Conservative Q1 guidance: EPS ≥$0.54 CER vs. $0.62 in Q4

What Did Management Guide?

FY 2026 Outlook :

Metric	FY 2026 Guidance	FY 2025 Actual	Implied Growth
Net Sales (CER)	≥+5%	+5% CER	Stable-to-accelerating
Adj. Diluted EPS (CER)	≥$2.50	$2.40 CER	≥+4%
Adj. Operating Margin	29.5%	29.5%	Flat (offsetting headwinds)
Adj. Tax Rate	~18%	19%	Slight improvement

Q1 2026 Outlook :

Metric	Q1 2026 Guidance
Net Sales (CER)	≥+1%
Adj. Diluted EPS (CER)	≥$0.54
Currency Impact	+2-3 ppt positive on sales

The sequential step-down in Q1 EPS guidance ($0.54 vs. Q4's $0.62) reflects typical seasonality and currency movements.

What Changed From Last Quarter?

Key changes since Q3 2025:

Item	Q3 2025	Q4 2025	Change
Adj. Operating Margin	29.6%	28.6%	-100 bps (Q4 seasonality)
QuantiFERON Growth	+11% CER	+5% CER	Slowed (Q4'24 tender comps)
QIAstat-Dx Growth	+11% CER	+15% CER	Accelerated
NeuMoDx	Winding down	Fully discontinued	Complete exit

New developments:

Parse Biosciences acquisition closed December 2025
Blood culture ID panels submitted for regulatory approval
New Supervisory Board member: Mark Stevenson (former Thermo Fisher COO)

Growth Pillars

What Are the Growth Pillars Targeting?

QIAGEN's five growth pillars delivered $1.49B CER in FY 2025 (+8% CER), hitting their target:

Pillar	FY 2025 CER	2026 Target	2028 Target
Sample Technologies	$653M	~$720M	—
QuantiFERON	$501M	~$535M	—
QIAcuity	$87M	~$100M	—
QIAstat-Dx	$136M	~$160M	—
QDI	$112M	~$125M	—
Total Pillars	$1.49B	~$1.64B (+9%)	≥$2.0B

The 2028 target of ≥$2B from growth pillars implies a ~10% CAGR from 2025, with pillars growing faster than the overall company.

Ask Fintool AI Agent

What Are the Key Risks?

Near-term concerns highlighted:

H1 2026 Growth Slowdown: Only ~2-3% CER growth expected before H2 acceleration
Currency & Tariff Headwinds: ~1.5 ppt combined margin drag in 2026
Capital Spending Environment: QIAcuity instrument placements challenged by customer capex constraints
Integration Risk: Parse and Genoox acquisitions need successful integration
NeuMoDx Wind-Down Complete: ~2 ppt headwind to growth now fully absorbed

Balance Sheet Snapshot

Metric	Dec 2025	Dec 2024
Cash & Equivalents	$839M	$664M
Group Liquidity	$1.10B	$1.15B
Total Debt	$1.65B	$1.39B
Net Debt	$556M	$239M
Leverage (Net Debt/EBITDA)	0.7x	0.3x

Leverage increased due to acquisition funding (Parse Biosciences: $291M cash) and $742M in new debt issuance, partially offset by $534M debt repayment.

Forward Catalysts

2026 catalysts to watch:

Q1: Blood culture ID panel FDA decision; New Sample tech systems launch
H1: Parse integration progress; Franklin AI expansion to ≥14 solutions by 2028
H2: Growth acceleration to 7-8% CER; New product launches (QIAsprint Connect, QIAmini)
Full Year: Potential bolt-on acquisitions; Margin expansion despite headwinds

Ask Fintool AI Agent

Data sourced from QIAGEN Q4 2025 earnings presentation published February 5, 2026. Stock prices as of February 4, 2026 close and aftermarket trading.